Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Vertex Earnings: Robust Sales of Trikafta/Kaftrio Support Long-Term Growth and Diverse Pipeline Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product ...

More than 30,0000 additional patients worldwide who are currently untreated will be able to seek treatment using Vertex’s recently approved triple combination regimen, Trikafta/Kaftrio.

Total revenues rose 16% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). The company currently markets four CF products, Trikafta/Kaftrio ...

Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of its blockbuster CF medicine, Trikafta/Kaftrio (Trikafta’s brand name in Europe), in younger age groups.

But when she found out about the drug Trikafta, she started thinking, “we can manage this”. Cystic fibrosis is a condition that produces thick and sticky mucus and mainly affects the lungs and ...

Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Kaftrio as a combination therapy for CF patients aged two years and older with a ...